CJC-1295 won't be found on pharmacy shelves in Sils or anywhere else for that matter — this is a specialist compound available through a dedicated online market. The core insight for Sils researchers: sourcing CJC-1295 depends entirely on vendor quality evaluation, not geography — and the evaluation methodology is universal across all locations. What reliably differentiates top CJC-1295 vendors is comprehensive lot-matched testing data: HPLC for purity, mass spec for identity and weight verification, and endotoxin testing for safety documentation. This guide gives Sils researchers the methodology to evaluate CJC-1295 vendors systematically and source verified-quality CJC-1295 with confidence.
What Studies Say About CJC-1295
CJC-1295 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Sils studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
How to Source CJC-1295 — Vendor Guide
Vetting CJC-1295 vendors begins with the COA: access the batch-specific certificate prior to buying, not after. When reviewing a CJC-1295 COA, verify: the batch number traces to your order, HPLC purity is ≥98%, mass spec identifies the correct molecular weight, and endotoxin levels are below the threshold for research use. Positive vendor signals beyond COA quality: established track record of at least two years, customer service that can discuss analytical methods, and temperature-appropriate packaging with desiccant. Price is an poor proxy for CJC-1295 quality — research-grade synthesis and testing has real costs that do not compress without quality compromise, so significantly below-market pricing signals compromises.
Order CJC-1295 — ships to Sils
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not been through the clinical trial process required for pharmaceutical approval — its safety profile is defined by animal study data and limited human studies. Lyophilised CJC-1295 should be placed in the freezer at −20°C straight away; avoid repeatedly thawing and refreezing reconstituted peptide by aliquoting into single-use portions. Endotoxin testing in the CJC-1295 COA is non-negotiable — gram-negative bacterial endotoxins can trigger serious inflammatory reactions at very low concentrations, and no discount compensates for this missing data. Researchers using CJC-1295 alongside other research compounds should check the research literature for any reported interactions before proceeding with any multi-compound protocol.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
